EyePoint Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US30233G2093
USD
16.72
3.03 (22.13%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Arcutis Biotherapeutics, Inc.
Arbutus Biopharma Corp.
Nurix Therapeutics, Inc.
MacroGenics, Inc.
Coherus BioSciences, Inc.
EyePoint Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc.
Icosavax, Inc.
KalVista Pharmaceuticals, Inc.
Erasca, Inc.
Cullinan Therapeutics, Inc.
Why is EyePoint Pharmaceuticals, Inc. ?
1
The company has declared negative results for the last 4 consecutive quarters
  • INTEREST(9M) At USD 0.01 MM has Grown at inf%
  • OPERATING CASH FLOW(Y) Lowest at USD -190.59 MM
  • DEBT-EQUITY RATIO (HY) Highest at -95.09 %
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 59.70%, its profits have fallen by -89.2%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is EyePoint Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
EyePoint Pharmaceuticals, Inc.
99.88%
0.81
76.74%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
17.93%
EBIT Growth (5y)
-216.46%
EBIT to Interest (avg)
-58.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.06
Sales to Capital Employed (avg)
0.30
Tax Ratio
0.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.06
EV to EBIT
-1.85
EV to EBITDA
-1.87
EV to Capital Employed
-16.57
EV to Sales
5.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-49.19%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
NET SALES(HY)

At USD 29.79 MM has Grown at 40.76%

NET PROFIT(HY)

Higher at USD -104.62 MM

RAW MATERIAL COST(Y)

Fallen by -1.9% (YoY

-33What is not working for the Company
INTEREST(9M)

At USD 0.01 MM has Grown at inf%

OPERATING CASH FLOW(Y)

Lowest at USD -190.59 MM

DEBT-EQUITY RATIO (HY)

Highest at -95.09 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.96 times

NET SALES(Q)

Lowest at USD 5.33 MM

OPERATING PROFIT(Q)

Lowest at USD -61.69 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -1,156.74 %

PRE-TAX PROFIT(Q)

Lowest at USD -59.33 MM

NET PROFIT(Q)

Lowest at USD -59.43 MM

EPS(Q)

Lowest at USD -0.85

Here's what is working for EyePoint Pharmaceuticals, Inc.
Raw Material Cost
Fallen by -1.9% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for EyePoint Pharmaceuticals, Inc.
Interest
At USD 0.01 MM has Grown at inf%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Sales
At USD 5.33 MM has Fallen at -61.94%
over average net sales of the previous four periods of USD 14.01 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -59.33 MM has Fallen at -61.79%
over average net sales of the previous four periods of USD -36.67 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -59.43 MM has Fallen at -61.94%
over average net sales of the previous four periods of USD -36.7 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow
Lowest at USD -190.59 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debt-Equity Ratio
Highest at -95.09 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Net Sales
Lowest at USD 5.33 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (USD MM)

Operating Profit
Lowest at USD -61.69 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin
Lowest at -1,156.74 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit
Lowest at USD -59.33 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -59.43 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

EPS
Lowest at USD -0.85
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Inventory Turnover Ratio
Lowest at 0.96 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio